TMCnet News
Dermavant Sciences to Present Tapinarof Phase 2b Data on Patient-Reported Outcomes for Psoriasis and Atopic Dermatitis at the Fall Clinical Dermatology ConferenceBASEL, Switzerland, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that two abstracts containing Phase 2b data on patient-reported outcomes in psoriasis and atopic dermatitis from the company’s lead drug, tapinarof, will be presented in poster format during the upcoming 2018 Fall Clinical Dermatology Conference at the Wynn Hotel in Las Vegas from Oct. 18-21. Tapinarof is a therapeutic aryl hydrocarbon receptor modulating agent (TAMA) under investigation for the treatment of psoriasis and atopic dermatitis. Posters, dates/times, and location are listed below. Tapinarof Data: Patient-reported outcomes in subjects with plaque psoriasis treated with tapinarof cream: Results from a phase 2b, randomized parallel-group study. Neal Bhatia, M.D.,1 David Rubenstein, M.D., Ph.D.,2 Anna M. Tallman, Pharm.D.,3 James Lee, M.D., Ph.D.3 Patient-reported outcomes in subjects with atopic dermatitis treated with tapinarof cream: Resultsfrom a phase 2b, randomized parallel-group study. Amy S. Paller, M.D.,1 Linda Stein Gold, M.D.,2 James Lee, M.D., Ph.D.,3 Anna M. Tallman, Pharm.D.,3 David Rubenstein, M.D., Ph.D.4 Dates/Times:
Location:
About Dermavant For more information about Dermavant, please visit www.dermavant.com. CONTACT: |